Estadístiques de Expert consensus on the management of adverse events of Lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer

Visites totals

views
Expert consensus on the management of adverse events of Lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer 3

Visites totals per mes

views
October 2024 0
November 2024 0
December 2024 0
January 2025 0
February 2025 0
March 2025 0
April 2025 3

Visites al fitxer

views
Arriola_cdi_expe.pdf 12